2
Participants
Start Date
July 31, 2011
Primary Completion Date
November 30, 2011
Study Completion Date
October 31, 2012
VTX-2337 plus radiotherapy
Radiation on Day 1. On Day 2, VTX-2337 3.0mg/m2 is administered intratumorally, followed by radiation. VTX-2337 3.0mg/m2 is then given weekly for 3 weeks in a 4 week cycle over 3 cycles.
Stanford Cancer Center, Stanford
Lead Sponsor
Stanford University
OTHER
Celgene
INDUSTRY